, Tracking Stock Market Picks
Enter Symbol:
Crocs, Inc. (CROX) [hlAlert]

down 30.22 %

Crocs, Inc. (CROX) upgraded to Buy with price target $25 by Standpoint Research

Posted on: Thursday,  Apr 26, 2012  4:25 PM ET by Standpoint Research

Standpoint Research rated Buy Crocs, Inc. (NASDAQ: CROX) on 04/26/2012, when the stock price was $20.28. Since
then, Crocs, Inc. has lost 30.23% as of 01/13/2016's recent price of $14.15.
If you would have followed this Standpoint Research's recommendation on CROX, you would have lost 30.22% of your investment in 1357 days.

Crocs, Inc. is a rapidly growing designer, manufacturer and marketer of footwear for men, women and children under the CROCS brand. All of the Company's footwear products incorporate its proprietary closed-cell resin material, which the Company believes represents a substantial innovation in footwear comfort and functionality. The Company's proprietary closed-cell resin, which it refers to as Croslite enables Crocs to produce a soft and lightweight, non-marking, slip and odor-resistant shoe. These unique properties make the Company's footwear ideal for casual wear, as well as for recreational uses such as boating, hiking, fishing and gardening, and have enabled Crocs to successfully market its products to a broad range of consumers.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/26/2012 4:25 PM Buy
20.28 25.00
as of 12/31/2012
1 Week up  5.34 %
1 Month up  7.79 %
3 Months down  -11.22 %
1 YTD up  13.27 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/20/2012 8:25 AM Hold
2/17/2012 10:25 AM Hold
10/18/2011 11:25 AM Buy
16.55 21.00
10/14/2011 11:25 AM Hold
10/4/2011 4:25 PM Buy
23.21 28.00
9/27/2011 11:25 AM Hold
8/8/2011 4:25 PM Buy
25.45 31.00
5/10/2011 3:25 PM Hold
3/16/2011 4:25 PM Buy
17.09 22.00
2/11/2010 4:25 PM Hold
11/9/2009 10:25 AM Buy
5.64 10.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy